Results indicated that the proportions of Tregs in CD4+ T cells (Figure S3A,B) and of CD3+ T cells in lymphocytes (Figure S4A,B) in PBMCs of tumor‐bearing mice treated with NU7441 were also significantly reduced. This evidence concerns the gene CD4 and neoplasm.